Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression

International Journal of Obesity

Volumn 38, Issue 5, 2014, Pages 737-745

  Ortega, F J ^a,b   Moreno Navarrete, J M ^a,b   Mayas, D ^a,c   Serino, M ^d   Rodriguez Hermosa, J I ^b   Ricart, W ^a,b   Luche, E ^d   Burcelin, R ^d   Tinahones, F J ^a,c   Fruhbeck G ^a,e   Mingrone, G ^f   Fernandez Real J M ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

adipocytes; adipose tissue; inflammation; insulin resistance; tumor protein 53; type 2 diabetes

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; PROTEIN P53; RNA; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CELL ISOLATION; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION; ADIPOGENESIS; ANALYSIS OF VARIANCE; ANIMAL; BARIATRIC SURGERY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; OMENTUM; SURGERY; TUMOR SUPPRESSOR GENE;

MUS;

ADIPOCYTES; ADIPOGENESIS; ADIPOSE TISSUE; ANALYSIS OF VARIANCE; ANIMALS; BARIATRIC SURGERY; DIET, HIGH-FAT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENES, P53; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; METFORMIN; MICE; MICE, KNOCKOUT; OBESITY; OMENTUM; THIAZOLIDINEDIONES;

EID: 84899900077     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2013.163     Document Type: Article

References (37)

1. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749-758.
2. Benoit V, de Moraes E, Dar NA, Taranchon E, Bours V, Hautefeuille A et al. Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene 2006; 25: 5708-5718.
3. Maddocks OD, Vousden KH. Metabolic regulation by p53. J Mol Med (Berl) 2011; 89: 237-245.
4. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-445.
5. Shimizu I, Yoshida Y, Katsuno T, Minamino T. Adipose tissue inflammation in diabetes and heart failure. Microbes Infect 2013; 15: 11-17.
6. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788.
7. Moreno-Navarrete JM, Ortega F, Sabater M, Ricart W, Fernandez-Real JM. Telomere length of subcutaneous adipose tissue cells is shorter in obese and formerly obese subjects. Int J Obes (Lond) 2010; 34: 1345-1348.
8. Minamino T, Orimo M, Shimizu I, Kunieda T, Yokoyama M, Ito T et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med 2009; 15: 1082-1087.
9. Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc Natl Acad Sci USA 1991; 88: 8982-8986.
10. Wang X, Kua HY, Hu Y, Guo K, Zeng Q, Wu Q et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 2006; 172: 115-125.
11. Zambetti GP, Horwitz EM, Schipani E. Skeletons in the p53 tumor suppressor closet: genetic evidence that p53 blocks bone differentiation and development. J Cell Biol 2006; 172: 795-797.
12. Bazuine M, Stenkula KG, Cam M, Arroyo M, Cushman SW. Guardian of corpulence: a hypothesis on p53 signaling in the fat cell. Clin Lipidol 2009; 4: 231-243.
13. Kichina J, Green A, Rauth S. Tumor suppressor p53 down-regulates tissue-specific expression of tyrosinase gene in human melanoma cell lines. Pigment Cell Res 1996; 9: 85-91.
14. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004; 64: 2627-2633.
15. Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A et al. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One 2008; 3: e3707.
16. de la Torre AJ, Rogoff D, White PC. p53 and cellular glucose uptake. Endocr Res 2013; 38: 32-39.
17. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008; 134: 451-460.
18. Bensaad K, Vousden KH. Savior and slayer: the two faces of p53. Nat Med 2005; 11: 1278-1279.
19. Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C. Adipose-derived stem cells: isolation, expansion and differentiation. Methods 2008; 45: 115-120.
20. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2013; 366: 1577-1585.
21. Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa JI, Sabater M, Pardo G, Ricart W et al. OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes 2011; 60: 168-176.
22. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772.
23. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B. Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 2002; 282: E834-E842.
24. Ortega FJ, Vazquez-Martin A, Moreno-Navarrete JM, Bassols J, Rodriguez-Hermosa J, Girones J et al. Thyroid hormone responsive Spot 14 increases during differentiation of human adipocytes and its expression is down-regulated in obese subjects. Int J Obes (Lond) 2010; 34: 487-499.
25. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996; 2: 1254-1258.
26. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000; 404: 892-897.
27. Wu H, Lozano G. NF-kappa B activation of p53.A potential mechanism for suppressing cell growth in response to stress. J Biol Chem 1994; 269: 20067-20074.
28. Webster GA, Perkins ND. Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 1999; 19: 3485-3495.
29. Jackson MW, Berberich SJ. Constitutive mdmx expression during cell growth, differentiation, and DNA damage. DNA Cell Biol 1999; 18: 693-700.
30. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13: 927-934.
31. Chang J, Wittert G. Effects of bariatric surgery on morbidity and mortality in severe obesity. Int J Evid Based Healthc 2009; 7: 43-48.
32. Thoreen CC, Sabatini DM. AMPK and p53 help cells through lean times. Cell Metab 2005; 1: 287-288.
33. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N et al. In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol 2011; 668: 373-382.
34. Hall JL, Matter CM, Wang X, Gibbons GH. Hyperglycemia inhibits vascular smooth muscle cell apoptosis through a protein kinase C-dependent pathway. Circ Res 2000; 87: 574-580.
35. Ruiz E, Gordillo-Moscoso A, Padilla E, Redondo S, Rodriguez E, Reguillo F et al. Human vascular smooth muscle cells from diabetic patients are resistant to induced apoptosis due to high Bcl-2 expression. Diabetes 2006; 55: 1243-1251.
36. Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987; 10: 563-566.
37. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes 1986; 35: 990-998.